Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LRMR - Larimar Therapeutics, Inc.

IEX Last Trade
3.98
0.020   0.503%

Share volume: 10,740
Last Updated: Fri 27 Dec 2024 08:30:28 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$3.96
0.02
0.51%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
26%
Profitability 25%
Dept financing 6%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.88%
1 Month
-39.83%
3 Months
-39.19%
6 Months
-45.65%
1 Year
-15.18%
2 Year
0.38%
Key data
Stock price
$3.98
P/E Ratio 
0.00
DAY RANGE
$3.86 - $4.01
EPS 
$0.00
52 WEEK RANGE
$3.99 - $13.68
52 WEEK CHANGE
-$12.20
MARKET CAP 
504.710 M
YIELD 
N/A
SHARES OUTSTANDING 
63.807 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
1.70
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,185,576
AVERAGE 30 VOLUME 
$1,127,857
Company detail
CEO: Carole S. Ben-Maimon
Region: US
Website: larimartx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia.

Recent news